The performance-monitoring software maker has quietly rebuilt its balance sheet, ending FY2026 with a cash pile 27 per cent larger even as revenue guidance points to a 17 per cent slide. A swing to losses and an unproven product pivot leave the turnaround far from settled.

A cash-rich minnow with a shrinking top line

Few small-cap software stories are as paradoxical as Integrated Research Limited (ASX: IRI). The Sydney-based company, which builds monitoring and analytics software that watches over the payment systems, contact centres and networks of large enterprises, has just told the market it is sitting on more cash than in years — even as sales keep shrinking. For income-focused investors drawn by a headline yield near 7 per cent, and for contrarians betting on a technology turnaround, the numbers cut both ways.

What the company does

Integrated Research sells software under the Prognosis brand that helps organisations detect and diagnose faults in mission-critical systems before customers notice them. Historically it earned much of its money from upfront perpetual licences — large, lumpy payments recognised in the year a deal closes — plus ongoing maintenance and support. That model produces volatile revenue: a strong renewals year flatters results, a thin one guts them. Management is now trying to shift the mix toward subscription and consumption-based pricing, where customers pay a recurring fee over time. Recurring revenue — income that repeats each period rather than depending on one-off sales — is the metric the market is watching most closely.

The latest catalyst

On 24 July 2026, Integrated Research issued an unaudited trading update for the financial year ended 30 June 2026. It guided to statutory revenue of A$56–58 million, down roughly 17 per cent on the A$68.3 million reported in FY2025, and pro forma revenue of A$64–66 million, a milder 13 per cent decline. The company expects to swing to an EBITDA loss of between A$2 million and A$4 million, against a A$15.9 million EBITDA profit a year earlier. Management blamed a softer renewals book, weaker second-half new business, expected credit losses and foreign-exchange headwinds, adding that customers were making "more cautious technology investment decisions" as they weigh up artificial intelligence. Several deals had slipped into the first half of FY2027.

The bright spot was the balance sheet. Cash rose to A$51.7 million, up 27 per cent from A$40.6 million a year earlier — the figure that anchors the more optimistic reading of this stock.

The dividend question

Here the headline needs care. Integrated Research suspended its dividend during its post-pandemic earnings slump and only resumed payments in the 2024 financial year, at a heavily reduced 2.0 cents per share, fully franked. It paid the same 2.0 cents as a final dividend for FY2025 (ex-dividend 3 September 2025) and declared no interim dividend for the first half of FY2026.

Measured against the last close of A$0.295 on 3 August 2026, the trailing 2.0-cent payout equates to an indicative yield of about 6.8 per cent, or roughly 9.7 per cent once franking credits are grossed up. That is genuinely attractive — but it is a backward-looking figure. With FY2026 now expected to show an EBITDA loss and no interim dividend paid, whether the board declares a final dividend when full-year results land, likely in late August 2026, is an open question. Past dividends are no guarantee of future payments.

Outlook

The company frames its weak numbers as the cost of transformation. Its "product-led growth" strategy leans on newly launched products: Iris, a conversational AI interface for monitoring multi-vendor technology environments; Prognosis Elevate, a cloud-hosted, as-a-service deployment option; and IR Labs, which targets a beta of an AI-powered standalone product in calendar 2026. Management has been candid that "profit will remain pressured in the short to medium term" while it invests. These are company statements and guidance, not independently verified outcomes.

The bull case

The optimistic view is straightforward. Integrated Research has a sticky base of blue-chip customers, a fortress balance sheet with no debt and cash covering close to half its market value, and a product refresh aimed squarely at the shift to cloud and AI. If the subscription and consumption model gains traction — the surge in expansion revenue is an early sign — recurring income could stabilise the top line and, eventually, restore margins. On that reading, a buyer today is paying only a modest premium to net cash for an established software franchise mid-turnaround.

The risks

The risks are equally clear. Revenue has fallen in three of the past four financial years on a statutory basis, and FY2026 guidance implies the decline is accelerating, not easing. Churn is currently outrunning new business. A pivot to subscriptions typically depresses reported revenue before rebuilding it, with no guarantee the rebuild materialises — especially if enterprise AI budgets crowd out legacy monitoring tools. An EBITDA loss, deferred deals and a paused interim dividend all point to real operational pressure. And a cash balance, however comforting, can be eroded by sustained losses.

Conclusion

Integrated Research is, on the evidence, exactly the situation its viral framing suggests: a cash-rich, shrinking software company asking investors to believe its next act will beat its last. The 27 per cent cash increase is real and current; the revenue slide is equally real; and the near-7 per cent yield, while genuine on a trailing basis, rests on a payout the company has already trimmed once and may not sustain. Nothing here is advice — but the tension between a strong balance sheet and a weakening business is the whole story, and the FY2026 results due later this month should sharpen it considerably.